Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7019044 | 0.82 | MAOA (0.33) | MAOA | |
| SCHEMBL4743254 | 0.82 | APLNR (0.41) | APLNR | |
| SCHEMBL7348348 | 0.73 | MAOA (0.37) | MAOA | |
| SCHEMBL6769741 | 0.72 | HTR6 (0.37) | MAOA | |
| SCHEMBL4775469 | 0.69 | MAPT (0.39) | MAOA | |
| SCHEMBL1318768 | 0.67 | — | — | |
| SCHEMBL29085808 | 0.64 | — | — | |
| SCHEMBL15110674 | 0.62 | — | — | |
| SCHEMBL209169 | 0.62 | — | — | |
| SCHEMBL27529688 | 0.62 | SLC6A1 (0.31) | MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1997 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | claimed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | claimed |
| EP-1685119-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2016-03-09 | — | — | EP | claimed |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | APOLLOMICS INC. | 2015-08-06 | — | — | US | claimed |
| EP-2892904-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | Crown Bioscience Inc. (Taiwan) (CN) | 2015-07-15 | — | — | EP | claimed |
| EP-2340025-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-10-15 | — | — | EP | claimed |
| WO-2014032498-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | CROWN BIOSCIENCE INC. (TAICANG) (CN) | 2014-03-06 | — | — | WO | claimed |
| EP-2308812-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBVIE BAHAMAS LTD (BS) | 2014-02-26 | — | — | EP | claimed |
| EP-2326176-B1 | NON-AMIDIC LINKERS WITH BRANCHED TERMINI AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-09-18 | — | — | EP | claimed |
| WO-2011150338-A1 | METHODS OF TREATING OBESITY | ZAFGEN CORPORATION (US) | 2011-12-01 | — | — | WO | claimed |
| EP-1725544-B1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-05-27 | — | — | EP | claimed |
| EP-1066286-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOPYRAZINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-04-29 | — | — | EP | claimed |
| US-7265143-B2 | C-4 substituted retinoids | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2007-09-04 | — | — | US | claimed |
| CN-1658873-A | New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | claimed |
| CN-1658834-A | Method of treating mucus hypersecretion | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-08-24 | — | — | CN | claimed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | claimed |
| US-6271235-B1 | VIRICIDE | AGOURON PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | claimed |
| EP-0641204-B1 | 17-ETHERS AND THIOETHERS OF 4-AZA-STEROIDS | MERCK & CO INC (US) | 2000-08-16 | — | — | EP | claimed |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | disclosed |
| EP-0390602-A1 | Neurotrophic peptides | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | MET, MYC, HGFAC | MAOA 4142/4885APLNR 1638/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MAOA 3609/4885APLNR 3124/4885 |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | CTNNB1, WNT1, CTNND1 | MAOA 4530/4885APLNR 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.